LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Optimi Health: Early Warning Press Release in Accordance with National Instrument 62-103

April 04, 2024 | Last Trade: C$0.16 0.02 -11.11

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 110,000 common shares (each a "Common Share") of Optimi Health Corp. (the "Issuer") pursuant to acquisitions in the public market. The Common Shares of the Issuer are listed on the CSE under the trading symbol "OPTI".

Prior to giving effect to the foregoing acquisition of Common Shares, the Acquiror owned and/or had control over an aggregate of 8,875,483 Common Shares, representing approximately 9.96% of the issued and outstanding Common Shares of the Issuer on an undiluted basis. Following completion of the acquisition of the Common Shares, the Acquiror owns or has control or direction over, directly or indirectly, 8,985,483 Common Shares, 166,666 warrants, 450,000 stock options and 15,750 restricted share rights, representing approximately 10.09% of the issued and outstanding Common Shares of the Issuer on an undiluted basis and approximately 10.72% of the total issued and outstanding Common Shares of the Issuer on a partially diluted basis.

The Acquiror may acquire additional securities or dispose of securities of the Issuer in the future either on the open market, privately or otherwise depending on market conditions, reformulation of plans, other available investment business opportunities and/or other relevant factors.

For further information or to receive a copy of the early warning report filed by the Acquiror with securities regulatory authorities in Canada in connection with this press release, please contact Leah Hodges at (604) 377-0403 or refer to the Issuer's SEDAR+ profile at www.sedarplus.ca.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page